Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02627859
Recruitment Status : Unknown
Verified September 2016 by Bioventus LLC.
Recruitment status was:  Active, not recruiting
First Posted : December 11, 2015
Last Update Posted : September 21, 2016
Sponsor:
Information provided by (Responsible Party):
Bioventus LLC

Brief Summary:
26 week open label study of treatment with Durolane for OA pain of the ankle

Condition or disease Intervention/treatment Phase
Osteoarthritis Device: Durolane SJ Phase 4

Detailed Description:
Single injection Durolane in patients with mild to moderate OA of the ankle.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle
Study Start Date : June 2014
Actual Primary Completion Date : August 2016
Estimated Study Completion Date : October 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Durolane SJ
Durolane SJ intra-articular injection; device
Device: Durolane SJ
1ml single intra-articular injection in ankle




Primary Outcome Measures :
  1. AOS pain subscale score [ Time Frame: at 26 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Females or males between the ages of 19 and 85 years of age
  2. Diagnosis of mild to moderate (K-L grade II or III) osteoarthritis (OA) of the study ankle joint, confirmed by radiographs taken within the previous six months OA in the contralateral ankle is permissible provided that OA symptoms are greater in the study ankle.
  3. VAS (100mm) AOS pain subscale score in the range of 30mm to 90mm for the study ankle
  4. Must be willing to discontinue use of oral and topical analgesia other than rescue use of acetaminophen for any pain including OA pain in the study ankle. Must also be willing to discontinue acetaminophen rescue medication for at least 24 hours before each study visit
  5. Abstinence from any IA or peri-articular injections in the study ankle during the course of the trial, except for the Investigational Product
  6. Cooperative and able to communicate effectively with the Investigators
  7. Patients with chronic ankle pain of the study ankle lasting more than 6 months without clinically significant improvement in ankle pain over the past one month
  8. Body mass index (BMI) ≤ 35 kg/m2.
  9. English literacy and ability to understand and complete all informed consent procedures

Exclusion Criteria:

  1. Significant pain from other joints or low back pain requiring chronic ongoing analgesic therapy
  2. Hindfoot deformities
  3. Substantial venous or lymphatic stasis in the legs
  4. Presence of one or more conditions that could confound pain and functional assessments in the study ankle, e.g., plantar fasciitis, Achilles tendonitis, sprains of the foot, or degenerative joint disease of the foot.
  5. Clinically-apparent tense effusion, signs of misalignment or instability in the study ankle
  6. Ankle x-ray findings of acute fractures, severe loss of bone density, avascular necrosis and/or severe deformity in the study ankle
  7. Surgery to the study ankle within the previous 12 months
  8. Unable to abstain treatment with NSAIDs or any pain management medications during the week (or five half-lives of the drug, whichever is longer) prior to Baseline Visit.
  9. Unable to abstain from treatment with topical analgesics during the washout period prior to screening visit and throughout the duration of the study. Washout period for topical analgesics is based on clinical investigator judgment (~ a few days).
  10. Inability to tolerate acetaminophen for rescue medication use.
  11. IA or local peri-articular corticosteroid injections to the study ankle within the previous three months; or to any other joint within the previous month; or any oral corticosteroid within the previous month. Steroid inhalants are permitted if the patient has been on a stable regimen for the past month and remains on this regimen throughout the course of the trial
  12. IA injections with hyaluronic acid in the study ankle within the last 9 months
  13. Previous allergic reaction to a HA or lidocaine product allergies.
  14. Treatment with glucosamine/chondroitin sulfate initiated within the past three months, or dosage not stable for the past three months
  15. Change in physical therapy for the study ankle within one month preceding screening, or expected change in physical therapy for the ankle during the study
  16. Planned surgical procedure during the study period.
  17. Previous history or presence of septic arthritis in study ankle
  18. Active skin disease or infection in the area of the injection site
  19. Alcohol or drug abuse as determined by the Investigator or use of alcohol for control of pain; Use of illicit drugs including cannabis.
  20. Systemic inflammatory condition or autoimmune disease or infection such as rheumatoid arthritis, inflammatory arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, gout/ acute pseudo gout or any other connective tissue disease
  21. Uncontrolled hypothyroidism
  22. Treatment with anticoagulant (except for acetylsalicylic acid maximum of 325mg/day)
  23. Any medical condition which in the opinion of the investigator makes the patient unsuitable for inclusion (e.g., severe progressive chronic disease, malignancy, bleeding disorder, fibromyalgia)
  24. Pregnant or breast-feeding woman or woman of child-bearing potential not practicing adequate contraception.
  25. Subjects that in the opinion of the investigator are unsuitable for inclusion (e.g., subjects not likely to avoid other therapies, subjects not likely to stay in the study or with plans to relocate during the whole study period, or subjects likely to be unreliable)
  26. Concurrent participation in any other clinical study or participation within the preceding 30 days

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02627859


Locations
Layout table for location information
Canada, British Columbia
Providence Health Care
Vancouver,, British Columbia, Canada, V6Z-2A5
Sponsors and Collaborators
Bioventus LLC
Investigators
Layout table for investigator information
Principal Investigator: Alistair Younger, MD St. Pauls Hospital

Layout table for additonal information
Responsible Party: Bioventus LLC
ClinicalTrials.gov Identifier: NCT02627859     History of Changes
Other Study ID Numbers: 13DUR502
First Posted: December 11, 2015    Key Record Dates
Last Update Posted: September 21, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents